WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

Rhea-AI Summary

WuXi AppTec (WUXAY), a global pharmaceutical and life sciences technology platform company, has released a positive profit alert for H1 2025. The company expects total revenue of RMB20.80 billion, up 20.6% year-over-year, with revenue from Continuing Operations growing 24.2%.

Key financial highlights include an expected adjusted non-IFRS net profit of RMB6.31 billion (up 44.4% YoY), net profit after non-recurring items of RMB5.58 billion (up 26.5% YoY), and net profit attributable to owners of RMB8.56 billion (up 101.9% YoY). Basic earnings per share is projected at RMB3.01, representing a 106.2% increase.

Positive

• Total revenue growth of 20.6% YoY to RMB20.80 billion
• Adjusted non-IFRS net profit surge of 44.4% YoY to RMB6.31 billion
• Impressive 101.9% YoY increase in net profit attributable to owners
• Strong 106.2% YoY growth in basic earnings per share to RMB3.01
• Continuing Operations showing robust 24.2% YoY revenue growth

Negative

• Growth rate impacted by exchange rate fluctuations

News Market Reaction

+6.59%

1 alert

+6.59% News Effect

On the day this news was published, WUXAY gained 6.59%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SHANGHAI, July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a Positive Profit Alert for the first half of 2025 and disclosed key operational data forecasts.

Important notice of the announcement are as follows:

WuXi AppTec maintains a laser focus on the Company's unique, integrated and end-to-end CRDMO (Contract Research, Development and Manufacturing Organization) business model. In response to customers' ongoing demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. These factors are driving sustained long-term business growth, delivering highly efficient and exceptional services to customers and helping to bring groundbreaking therapies to patients worldwide.

• Total revenue for the first half of 2025 is expected to be approximately RMB20.80 billion, representing a year-over-year increase of approximately 20.6%, with revenue from Continuing Operations growing by approximately 24.2% year-over-year.
• Adjusted non-IFRS net profit for the first half of 2025 is expected to be approximately RMB6.31 billion, representing a year-over-year increase of approximately 44.4%.
• Net profit after deducting non-recurring items^[1] for the first half of 2025 is expected to be approximately RMB5.58 billion, representing a year-over-year increase of approximately 26.5%. The growth rate compared to the adjusted non-IFRS net profit is mainly affected by exchange rate fluctuations.
• Net profit attributable to the owners of the Company^[1] for the first half of 2025 is expected to be approximately RMB8.56 billion, representing a year-over-year increase of approximately 101.9%, which includes the gain on partial disposal of associates. Basic earnings per share for the first half of 2025 is expected to be approximately RMB3.01, representing a year-over-year increase of approximately 106.2%.

WuXi AppTec will provide additional details when the Company releases its results for the first half of 2025 on July 29, 2025.

For more information, please refer to the Company's related announcements: Positive Profit Alert.

^[1] Net profit after deducting non-recurring items and net profit attributable to the owners of the Company are both prepared in accordance with China Accounting Standards for Business Enterprises (CAS).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer an integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

FAQ

What are WuXi AppTec's (WUXAY) expected earnings for H1 2025?

WuXi AppTec expects adjusted non-IFRS net profit of RMB6.31 billion for H1 2025, representing a 44.4% increase year-over-year.

What is WuXi AppTec's projected revenue for the first half of 2025?

WuXi AppTec projects total revenue of RMB20.80 billion for H1 2025, showing a 20.6% increase year-over-year.

How much will WuXi AppTec's earnings per share grow in H1 2025?

WuXi AppTec expects basic earnings per share of RMB3.01 for H1 2025, representing a 106.2% increase year-over-year.

When will WuXi AppTec release its full H1 2025 financial results?

WuXi AppTec will release its complete H1 2025 financial results on July 29, 2025.

What factors are driving WuXi AppTec's growth in 2025?

WuXi AppTec's growth is driven by its integrated CRDMO business model, enhanced capabilities and capacity, optimized production processes, and improved operating efficiency in response to customer demand.